The high-grade glioma market is witnessing steady growth driven by the rising incidence of aggressive brain tumors, increasing awareness, and advancements ...

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies< Extends NeOnc’s ...

COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, ...

COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today anno ...

Patients with newly diagnosed glioblastoma received individualized total doses of ITM-31 in three fractions with an interval of 4 weeks between injections after completion of standard of care therapy.

Glioblastoma claims the lives of 200,000 people each year globally. Despite decades of research and funding, survival rates remain low.

The Scary Mommy founder revealed her glioblastoma diagnosis in 2024 after a seizure led doctors to discover a brain tumor.

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

Jill Smokler, the founder of Scary Mommy and a beloved author known for her honest depictions of motherhood, has tragically ...

A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common ...